S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable

Akero Therapeutics Stock Price, News & Analysis (NASDAQ:AKRO)

$16.52
+0.42 (+2.61%)
(As of 11/28/2023 ET)
Compare
Today's Range
$15.62
$16.55
50-Day Range
$11.38
$50.58
52-Week Range
$11.25
$58.38
Volume
676,203 shs
Average Volume
981,478 shs
Market Capitalization
$920.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.86

Akero Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
147.3% Upside
$40.86 Price Target
Short Interest
Bearish
11.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.11mentions of Akero Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$3.61 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.81) to ($3.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

238th out of 949 stocks

Pharmaceutical Preparations Industry

99th out of 435 stocks


AKRO stock logo

About Akero Therapeutics Stock (NASDAQ:AKRO)

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

AKRO Stock Price History

AKRO Stock News Headlines

Akero Therapeutics Inc AKRO
Akero Therapeutics (NASDAQ:AKRO) Shares Down 3% on Insider Selling
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Akero Therapeutics: Deceptively Promising
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
11 Analysts Have This to Say About Akero Therapeutics
Akero Therapeutics: Q3 Earnings Insights
Akero Therapeutics (NASDAQ: AKRO)
Akero Therapeutics' Disappointing NASH Data Drags Its Rival
Why Shares of 89bio Plummeted on Tuesday
Why Is Liver Disease Focused Akero Therapeutics Stock Sinking Today?
Why Akero Therapeutics Stock Is Crashing Today
Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?
See More Headlines
Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/15/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKRO
Fax
N/A
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.86
High Stock Price Target
$58.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+147.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-112,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.98 per share

Miscellaneous

Free Float
50,312,000
Market Cap
$920.33 million
Optionable
Not Optionable
Beta
-0.73
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Andrew Cheng M.D. (Age 56)
    Ph.D., President, CEO & Director
    Comp: $1.22M
  • Dr. Jonathan M. Young J.D. (Age 53)
    Ph.D., Co-Founder, Executive VP, COO & Secretary
    Comp: $763.3k
  • Dr. Timothy Rolph (Age 69)
    Co-Founder & Chief Scientific Officer
    Comp: $819.4k
  • Mr. William R. White J.D. (Age 50)
    Executive VP, CFO, Treasurer & Head of Corporate Development
    Comp: $768.4k
  • Ms. Catriona  YaleMs. Catriona Yale (Age 51)
    Executive VP & Chief Development Officer
    Comp: $754.8k
  • Mr. Patrick Lamy (Age 50)
    Senior Vice President of Commercial Strategy
  • Mr. John J. Schembri (Age 61)
    VP of Finance & Controller














AKRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Akero Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKRO shares.
View AKRO analyst ratings
or view top-rated stocks.

What is Akero Therapeutics' stock price target for 2024?

8 brokers have issued twelve-month target prices for Akero Therapeutics' shares. Their AKRO share price targets range from $33.00 to $58.00. On average, they predict the company's share price to reach $40.86 in the next year. This suggests a possible upside of 147.3% from the stock's current price.
View analysts price targets for AKRO
or view top-rated stocks among Wall Street analysts.

How have AKRO shares performed in 2023?

Akero Therapeutics' stock was trading at $54.80 at the beginning of 2023. Since then, AKRO shares have decreased by 69.9% and is now trading at $16.52.
View the best growth stocks for 2023 here
.

When is Akero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 15th 2024.
View our AKRO earnings forecast
.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) released its earnings results on Monday, November, 13th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01.

What ETFs hold Akero Therapeutics' stock?
What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS).

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Akero Therapeutics' major shareholders?

Akero Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Alkeon Capital Management LLC (6.78%), FMR LLC (4.95%), Adage Capital Partners GP L.L.C. (3.49%), Redmile Group LLC (3.18%), Rock Springs Capital Management LP (2.55%) and Lord Abbett & CO. LLC (1.40%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White.
View institutional ownership trends
.

How do I buy shares of Akero Therapeutics?

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AKRO) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -